147 related articles for article (PubMed ID: 31964532)
1. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
Nishida S; Matsumura T; Senokuchi T; Murakami-Nishida S; Ishii N; Morita Y; Yagi Y; Motoshima H; Kondo T; Araki E
Biochem Biophys Res Commun; 2020 Mar; 524(1):8-15. PubMed ID: 31964532
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.
Zhuge F; Ni Y; Nagashimada M; Nagata N; Xu L; Mukaida N; Kaneko S; Ota T
Diabetes; 2016 Oct; 65(10):2966-79. PubMed ID: 27445264
[TBL] [Abstract][Full Text] [Related]
3. DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation.
Wang H; Li Y; Zhang X; Xu Z; Zhou J; Shang W
Drug Des Devel Ther; 2020; 14():3929-3940. PubMed ID: 33061298
[TBL] [Abstract][Full Text] [Related]
4. Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A
Virta J; Hellberg S; Liljenbäck H; Ståhle M; Silvola JMU; Huusko J; Söderström M; Knuuti J; Nuutila P; Ylä-Herttuala S; Gomez MF; Roivainen A; Saraste A
Atherosclerosis; 2020 Jul; 305():64-72. PubMed ID: 32386751
[TBL] [Abstract][Full Text] [Related]
5. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
Aroor AR; Habibi J; Kandikattu HK; Garro-Kacher M; Barron B; Chen D; Hayden MR; Whaley-Connell A; Bender SB; Klein T; Padilla J; Sowers JR; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2017 May; 16(1):61. PubMed ID: 28476142
[TBL] [Abstract][Full Text] [Related]
7. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
[TBL] [Abstract][Full Text] [Related]
9. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2017 Sep; 96-98():19-25. PubMed ID: 28347868
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo.
Ishida M; Shen WR; Kimura K; Kishikawa A; Shima K; Ogawa S; Qi J; Ohori F; Noguchi T; Marahleh A; Kitaura H
Biomed Pharmacother; 2019 Jan; 109():242-253. PubMed ID: 30396082
[TBL] [Abstract][Full Text] [Related]
11. DPP-4 inhibition by linagliptin ameliorates age-related mild cognitive impairment by regulating microglia polarization in mice.
Zhuge F; Zheng L; Pan Y; Ni L; Fu Z; Shi J; Ni Y
Exp Neurol; 2024 Mar; 373():114689. PubMed ID: 38199510
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice.
Hasegawa Y; Hayashi K; Takemoto Y; Cheng C; Takane K; Lin B; Komohara Y; Kim-Mitsuyama S
Cardiovasc Diabetol; 2017 Dec; 16(1):154. PubMed ID: 29195509
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice.
Silva-Veiga FM; Miranda CS; Vasques-Monteiro IML; Souza-Tavares H; Martins FF; Daleprane JB; Souza-Mello V
World J Gastroenterol; 2022 May; 28(17):1814-1829. PubMed ID: 35633911
[TBL] [Abstract][Full Text] [Related]
14. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
[TBL] [Abstract][Full Text] [Related]
15. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages.
Hiromura M; Nohtomi K; Mori Y; Kataoka H; Sugano M; Ohnuma K; Kuwata H; Hirano T
Biochem Biophys Res Commun; 2018 Jan; 495(1):223-229. PubMed ID: 29113797
[TBL] [Abstract][Full Text] [Related]
17. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
[TBL] [Abstract][Full Text] [Related]
18. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
Sakai Y; Chen G; Ni Y; Zhuge F; Xu L; Nagata N; Kaneko S; Ota T; Nagashimada M
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32790863
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
Hasan AA; von Websky K; Reichetzeder C; Tsuprykov O; Gaballa MMS; Guo J; Zeng S; Delić D; Tammen H; Klein T; Kleuser B; Hocher B
Kidney Int; 2019 Jun; 95(6):1373-1388. PubMed ID: 30979564
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin decreased the tumor progression on glioblastoma model.
Tsuji S; Kudo U; Hatakeyama R; Shoda K; Nakamura S; Shimazawa M
Biochem Biophys Res Commun; 2024 Jun; 711():149897. PubMed ID: 38608433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
